S
ONE TO WATCH:
John Orwin, SVP, Sales and Marketing, BioOncology, Genentech
Orwin learned the landscape of onoclogy while working as senior director of oncology marketing at Alza, and then eventually as the franchise VP at J&J's Tibotec division. In 2005, he headed out to Cali to join Genentech, and was promoted the same year to head sales and marketing of its BioOncology division. And it's a good thing: Orwin was part of the commercial genius that built such heavyweights as Avastin, Herceptin, and Rituxan.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.